## Brian C Baumann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5975945/publications.pdf

Version: 2024-02-01

279701 302012 1,786 90 23 citations h-index papers

g-index 91 91 91 2792 citing authors docs citations times ranked all docs

39

#	Article	IF	CITATIONS
1	Selective Targeting of Brain Tumors with Gold Nanoparticle-Induced Radiosensitization. PLoS ONE, 2013, 8, e62425.	1.1	205
2	Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer. JAMA Oncology, 2020, 6, 237.	3.4	106
3	Theranostic Application of Mixed Gold and Superparamagnetic Iron Oxide Nanoparticle Micelles in Glioblastoma Multiforme. Journal of Biomedical Nanotechnology, 2016, 12, 347-356.	0.5	94
4	Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy. JAMA Surgery, 2018, 153, e174591.	2.2	68
5	Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection. Journal of Surgical Oncology, 2016, 114, 65-69.	0.8	63
6	Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. Cancer, 2020, 126, 3900-3906.	2.0	62
7	Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer, 2014, 120, 1272-1280.	2.0	60
8	NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1382-1394.	2.3	59
9	Bladder Cancer Patterns of Pelvic Failure: Implications for Adjuvant Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 363-369.	0.4	52
10	Neutrophilâ€toâ€lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer, 2017, 123, 794-801.	2.0	51
11	Enhancing the Efficacy of Drug-loaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy. Oncotarget, 2013, 4, 64-79.	0.8	51
12	A Novel Risk Stratification to Predict Local-Regional Failures in Urothelial Carcinoma of the Bladder After Radical Cystectomy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 81-88.	0.4	50
13	Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 78-86.	0.4	46
14	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. PLoS Medicine, 2021, 18, e1003732.	3.9	38
15	Stereotactic Intracranial Implantation and <em>In vivo </em> Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme. Journal of Visualized Experiments, 2012, , .	0.2	37
16	An Integrated Method for Reproducible and Accurate Image-Guided Stereotactic Cranial Irradiation of Brain Tumors Using the Small Animal Radiation Research Platform. Translational Oncology, 2012, 5, 230-237.	1.7	36
17	Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database. Journal of Urology, 2018, 199, 416-423.	0.2	36
18	Occult Pelvic Lymph Node Involvement in Bladder Cancer: Implications for Definitive Radiation. International Journal of Radiation Oncology Biology Physics, 2014, 88, 603-610.	0.4	35

#	Article	IF	CITATIONS
19	Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1118-1124.	0.6	32
20	Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma. Frontiers in Oncology, 2019, 9, 922.	1.3	32
21	Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder. European Urology Focus, 2018, 4, 900-906.	1.6	30
22	Urinary schistosomiasis and the associated bladder cancer: update. Journal of the Egyptian National Cancer Institute, 2020, 32, 44.	0.6	28
23	Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treatment Reviews, 2018, 70, 88-97.	3.4	26
24	A prospective clinical trial of proton therapy for chordoma and chondrosarcoma: Feasibility assessment. Journal of Surgical Oncology, 2019, 120, 200-205.	0.8	25
25	Multiâ€institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. Journal of Surgical Oncology, 2020, 122, 877-883.	0.8	24
26	Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation. Brachytherapy, 2017, 16, 291-298.	0.2	22
27	The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer, 2017, 3, 19-30.	0.2	22
28	A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate. Frontiers in Oncology, 2019, 9, 1378.	1.3	20
29	Adjuvant Radiation for Locally Advanced Bladder Cancer? A Question Worth Asking. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1040-1042.	0.4	19
30	Association Between Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma. JAMA Dermatology, 2021, 157, 540.	2.0	19
31	Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Journal of Urology, 2021, 206, 613-622.	0.2	18
32	A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database. Clinical and Translational Radiation Oncology, 2019, 15, 38-41.	0.9	17
33	Avoiding skin creams right before radiation: Myth or sound advice?. Journal of Clinical Oncology, 2015, 33, 51-51.	0.8	17
34	Adjuvant radiation therapy for bladder cancer: A dosimetric comparison of techniques. Medical Dosimetry, 2015, 40, 372-377.	0.4	16
35	Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 703-706.	0.4	14
36	Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images. Advances in Radiation Oncology, 2018, 3, 331-338.	0.6	14

#	Article	IF	CITATIONS
37	Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?. Translational Andrology and Urology, 2016, 5, 702-710.	0.6	13
38	Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery. Cancer, 2021, 127, 3591-3598.	2.0	13
39	Assessing the Validity of Clinician Advice That Patients Avoid Use of Topical Agents Before Daily Radiotherapy Treatments. JAMA Oncology, 2018, 4, 1742.	3.4	12
40	Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Medicine, 2019, 8, 3698-3709.	1.3	12
41	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics, 2021, 11, 9721-9737.	4.6	12
42	Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience. Journal of Contemporary Brachytherapy, 2019, 11, 399-408.	0.4	11
43	Regional lymph node irradiation in locally advanced Merkel cell carcinoma reduces regional and distant relapse and improves disease-specific survival. Radiotherapy and Oncology, 2021, 155, 246-253.	0.3	11
44	Laparoscopic Versus Open Resection for Gastrointestinal Stromal Tumors (GISTs). Journal of Gastrointestinal Cancer, 2017, 48, 20-24.	0.6	10
45	Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospitalâ€based analysis of patterns of care, RT fractionation scheme, and overall survival. Cancer Medicine, 2018, 7, 4240-4250.	1.3	10
46	Anesthesia for ocular trauma. Current Anaesthesia and Critical Care, 2010, 21, 184-188.	0.3	9
47	Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 76-85.	2.0	9
48	The Importance of Temporary Telehealth Parity Laws to Improve Public Health During COVID-19 and Future Pandemics. International Journal of Radiation Oncology Biology Physics, 2020, 108, 362-363.	0.4	9
49	Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer. Journal of Contemporary Brachytherapy, 2019, 11, 320-328.	0.4	8
50	Reduced Wide Local Excision Margins are Associated with Increased Risk of Relapse and Death from Merkel Cell Carcinoma. Annals of Surgical Oncology, 2021, 28, 3312-3319.	0.7	8
51	Astrocyte-elevated gene-1 (AEG-1): Glioblastoma's helping hand during times of hypoxia and glucose deprivation?. Cancer Biology and Therapy, 2011, 11, 40-42.	1.5	7
52	Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. Clinical Genitourinary Cancer, 2021, 19, 41-46.e1.	0.9	7
53	Quantitative Analysis of Practice Size Consolidation in Radiation Oncology: A Trend Toward Bigger and Fewer Practices. Practical Radiation Oncology, 2021, 11, 328-338.	1.1	7
54	Emotional support animals on commercial flights: a risk to allergic patients. Lancet Respiratory Medicine, the, 2016, 4, 544-545.	5.2	6

#	Article	IF	CITATIONS
55	Impact of Facility Radiation Patient Volume on Overall Survival in Patients with Muscle Invasive Bladder Cancer Undergoing Trimodality Bladder Preservation Therapy. Bladder Cancer, 2019, 5, 235-244.	0.2	6
56	Development and validation of contouring guidelines for post-cystectomy adjuvant radiation of bladder cancer Journal of Clinical Oncology, 2016, 34, 409-409.	0.8	6
57	Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and Computed Tomography and Magnetic Resonance Imaging Simulation for External Beam Radiation Therapy for Low-Risk and Intermediate-Risk Prostate Cancer. Practical Radiation Oncology, 2022, 12, e117-e122.	1.1	5
58	Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy. European Urology Oncology, 2022, 5, 246-250.	2.6	5
59	Avoiding antiperspirants during breast radiation therapy: Myth or sound advice?. Radiotherapy and Oncology, 2017, 124, 204-207.	0.3	4
60	Review: Brain Metastases in Bladder Cancer. Bladder Cancer, 2020, 6, 237-248.	0.2	4
61	A Projection-Domain Low-Count Quantitative SPECT Method for É'-Particle-Emitting Radiopharmaceutical Therapy. IEEE Transactions on Radiation and Plasma Medical Sciences, 2023, 7, 62-74.	2.7	4
62	Concurrent chemo-radiotherapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy. British Journal of Cancer, 2020, 123, 869-870.	2.9	3
63	Falseâ€positive pregnancy test secondary to ectopic expression of human chorionic gonadotropin by a gastrointestinal stromal tumor. Journal of Surgical Oncology, 2020, 122, 809-812.	0.8	3
64	Technical Report: Development and Implementation of an Open Source Template Interpretation Class Library for Automated Treatment Planning. Practical Radiation Oncology, 2022, 12, e153-e160.	1.1	3
65	Re: Anatomical Patterns of Recurrence following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. Journal of Urology, 2016, 196, 961-962.	0.2	2
66	Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions Remain. International Journal of Radiation Oncology Biology Physics, 2021, 111, 113-116.	0.4	2
67	Mohs Surgical Site Infection Rates and Pathogens for the Mask-Covered Face During the COVID-19 Pandemic Versus the Pre-COVID Era. Dermatologic Surgery, 2021, 47, 1507-1510.	0.4	2
68	Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, 123-131.	0.9	2
69	Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer. European Urology Open Science, 2022, 37, 80-89.	0.2	2
70	Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy. Brachytherapy, 2022, 21, 617-625.	0.2	2
71	Effective Palliation of Intractable Bleeding from Noonan Syndrome-associated Lymphatic Malformations by Radiotherapy. Acta Dermato-Venereologica, 2015, 95, 1009-1010.	0.6	1
72	Palliative singleâ€fraction whole liver radiation therapy for diffuse liver metastases from metastatic Merkel cell carcinoma. Journal of Dermatology, 2020, 47, e375-e376.	0.6	1

#	Article	IF	CITATIONS
73	Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer. Brachytherapy, 2020, 19, 557-566.	0.2	1
74	Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2847-2848.	0.8	1
75	Assessing Inter-Fraction Changes in The Size and Position of The Penile Bulb During Daily MR-Guided Radiation Therapy to The Prostate Bed: Do We Need to Adjust How We Plan Radiation in The Post-Radical Prostatectomy Setting to Reduce Risk of Erectile Dysfunction?. Clinical Genitourinary Cancer, 2022	0.9	1
76	Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy. Journal of Urology, 2022, 207, 1227-1235.	0.2	1
77	Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer. Brachytherapy, 2022, , .	0.2	1
78	In Reply to Leung. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1128-1129.	0.4	0
79	Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG) Tj ETQq1 1 0.784314 rg	gBT¢ <b>@</b> verl	ocko10 Tf 50
80	Reply to: Dose-escalation of radiation may improve outcomes of squamous cell carcinoma of bladder. Clinical and Translational Radiation Oncology, 2020, 20, 52.	0.9	0
81	A Tailored Radiation Therapy Strategy for Older Patients With Localized Bladder Cancer Not Eligible for Curative Treatment. International Journal of Radiation Oncology Biology Physics, 2021, 110, 425-428.	0.4	0
82	Abstract 547: Urine tumor DNA MRD detection and correlation with pathologic complete response in muscle-invasive bladder cancer treated with curative-intent radical cystectomy. , 2021, , .		0
83	Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis. Clinical and Translational Radiation Oncology, 2021, 29, 47-53.	0.9	0
84	Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort Journal of Clinical Oncology, 2014, 32, 297-297.	0.8	0
85	Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer Journal of Clinical Oncology, 2015, 33, 347-347.	0.8	0
86	A Phase I/II Clinical Trial of Proton Therapy for Chordomas and Chondrosarcomas. , 2020, 81, .		0
87	Integrative analysis of urine cell-free DNA for the detection of residual disease in localized bladder cancer patients Journal of Clinical Oncology, 2022, 40, 559-559.	0.8	O
88	Survival outcomes in men with unfavorable intermediate-risk and high-risk prostate cancer treated with prostate-only versus whole pelvic radiation therapy Journal of Clinical Oncology, 2022, 40, 264-264.	0.8	0
89	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000245502.	0.2	0
90	Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 343-350.e4.	2.3	0